Navamedic ASA Expands with Acquisition of DNE Pharma Business
Deal News | Jun 23, 2025 | PR Newswire Cision Navamedic ASA
Navamedic ASA, a Nordic pharmaceutical entity, announced its acquisition of dne pharma’s business as a strategic move into the growing addiction treatment market. This acquisition, valued at NOK 225 million, will be paid in instalments with a substantial portion due at closing. Dne pharma, renowned for its addiction treatment products, will contribute to Navamedic’s goal of achieving NOK 1 billion in revenues. The acquisition complements Navamedic’s strategy to enhance its portfolio of proprietary products. To facilitate this acquisition, Navamedic is raising funds through a rights issue, supported by its primary shareholder, Kistefos AS. The rights issue aims to raise between NOK 110 million and NOK 130 million. Post-acquisition, Navamedic plans to integrate dne pharma’s products into its existing platform, expecting synergies and EBITDA improvements from the integration.
Sectors
- Pharmaceutical and Biotechnology
- Healthcare
- Financial Services
Geography
- Norway – Navamedic ASA and dne pharma are both Norwegian companies, and the business acquisition focuses on expanding Navamedic’s presence and influence within the Nordic region.
- Nordics – The acquisition aims at expanding Navamedic's market within the Nordic countries, enhancing its distribution network and customer base in this region.
- Europe – Navamedic aims to expand geographically across selected European markets following the acquisition, enhancing its footprint beyond the Nordic region.
Industry
- Pharmaceutical and Biotechnology – The article discusses Navamedic ASA's acquisition of dne pharma's business, which involves pharmaceutical products, particularly those targeting addiction treatment.
- Healthcare – The article highlights Navamedic's expansion into the healthcare sector, particularly in addiction treatment, strengthening its product offerings for hospitals and pharmacies.
- Financial Services – The article involves financial elements such as the rights issue and funding strategy to finance the acquisition, involving financial institutions and investors.
Financials
- NOK 225 million – Total consideration for the acquisition of dne pharma's business by Navamedic ASA.
- NOK 185 million – Initial payment at closing of the acquisition.
- NOK 40 million – Contingent payment based on achievement of sales volumes for the acquired products.
- NOK 110-130 million – Expected gross proceeds from the rights issue to help finance the acquisition.
- NOK 110 million – Amount underwritten by Kistefos AS for the rights issue.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Navamedic ASA | Acquirer | Company | A Nordic pharmaceutical company focused on delivering high-quality products to hospitals and pharmacies, aiming to expand into the addiction treatment market. |
| dne pharma | Target | Company | A Norwegian company focused on developing and distributing addiction and pain therapies, including opioid substitution treatments. |
| Kistefos AS | Underwriter | Company | Navamedic's largest shareholder, underwriting a minimum amount in the rights issue to finance the acquisition. |
| DNB Carnegie | Financial Advisor | Company | Financial advisor and manager for the rights issue related to the acquisition deal. |
| Nordea Bank Abp | Lender | Company | Providing debt and a bridge loan to facilitate the acquisition before the rights issue completion. |
| Advokatfirmaet Thommessen AS | Legal Advisor | Company | Norwegian legal counsel for Navamedic in connection with the acquisition and rights issue. |